Perspectum Lands Top Spot in Alantra Pharma Fast 50 Rankings. Read more

Our latest news

We are proud to be leading the way in providing more patient-centric solutions for people with liver disease that helps them and their physician make informed decisions about their care.

Read our latest news to find out more about how we are helping to improve the understanding of liver disease.

FDA awards funding to Perspectum and physicians at Massachusetts General Hospital to accelerate development of imaging biomarkers as drug development tools in liver disease Posted: December 14, 2020

Perspectum’s RADIcAL1 trial - addressing the health economic burden of invasive diagnostics for NAFLD and NASH Posted: December 9, 2020

RADIcAL NAFLD NASH LiverMultiScan Liver Disease New publication

Hepatica - new tool informs surgeons about previously undiagnosed background liver disease, helping to improve surgical decision-making in liver cancer care Posted: December 2, 2020

Hepatica liver cancer Liver Disease New publication

Post-conference Q&A - AASLD: The Digital Liver Meeting Experience Posted: December 2, 2020

Pharma AASLD

Perspectum presents new data, addressing key challenges of smart imaging Posted: November 29, 2020

CHRISTUS Shreveport-Bossier Health System and Perspectum Offer New Insights into Liver Health with LiverMultiScan Posted: November 17, 2020

Reversing fatty liver disease; New study in Hong Kong will use state-of-the-art clinical technology to evaluate different weight-loss methods Posted: November 17, 2020

LiverMultiScan

Perspectum launches new multiorgan imaging offering, Atlas®, for pharma sponsors at The Liver Meeting Digital Experience™ (TLMdX) 2020 Posted: November 10, 2020

Perspectum Releases New Whitepaper on The Cost-Effectiveness of Including Imaging in Phase 3 NASH Trials Posted: October 20, 2020

Pharma LiverMultiScan